Ratings Intco Medical Technology Co., Ltd.

Equities

300677

CNE100003456

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
22.79 ^CNY	+1.60%		+2.01%	-2.44%

Apr. 01	Tranche Update on Intco Medical Technology Co., Ltd.'s Equity Buyback Plan announced on July 13, 2023.	CI
Jan. 02	Tranche Update on Intco Medical Technology Co., Ltd.'s Equity Buyback Plan announced on July 13, 2023.	CI

Summary

According to Refinitiv, the company's ESG score for its industry is good.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
INTCO MEDICAL TECHNOLOGY CO., LTD.	-2.44%	2.01B	-	A-
COLOPLAST A/S	+18.73%	28.89B		B+
SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITED	-34.30%	2.83B		B-
WINNER MEDICAL CO., LTD.	-8.99%	2.7B		C+
HARTALEGA HOLDINGS	-0.74%	1.88B		B
HARBIN FUERJIA TECHNOLOGY CO., LTD.	-11.44%	1.79B	-	-
TOP GLOVE CORPORATION BHD.	-6.11%	1.37B		B
KOSSAN RUBBER INDUSTRIES	+14.59%	1.13B		C
KANGJI MEDICAL HOLDINGS LIMITED	+3.86%	1.06B		-
GVS S.P.A.	-0.63%	1.02B		B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes